Advice

in the absence of a submission from the holder of the marketing authorisation:

raltegravir (Isentress®) is not recommended for use within NHSScotland.

Indication under review: in combination with other anti-retroviral medicinal products in the treatment of human immunodeficiency virus in neonates.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download detailed advice135KB (PDF)

Download

Medicine details

Medicine name:
raltegravir (Isentress)
SMC ID:
SMC2101
Indication:
in combination with other anti-retroviral medicinal products in the treatment of human immunodeficiency virus in neonates.
Pharmaceutical company
MSD
BNF chapter
Infections
Submission type
Non submission
Status
Not recommended
Date advice published
09 July 2018